Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer

References

• Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;17(3):CD004064.
   Google Scholar
• Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–221. Mar
   PubMed Web of Science ®Google Scholar
• Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, et al. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer. 2014;110(5):1163–1168. 4
   PubMed Web of Science ®Google Scholar
• Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23(5):460–464. Sep
   PubMed Web of Science ®Google Scholar
• Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21(7):1395–1403. Jul
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. JCO. 2000;18(16):2938–2947. Aug
   PubMed Web of Science ®Google Scholar
• Zaniboni A, Meriggi F. The emerging role of oxaliplatin in the treatment of gastric cancer. J Chemother. 2005;17(6):656–662. Dec
   PubMed Web of Science ®Google Scholar
• Shah MA, Bang Y-J, Lordick F, Alsina M, Chen M, Hack SP, Bruey JM, Smith D, McCaffery I, Shames DS, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 2017;3(5):620–627. May 1
   PubMed Web of Science ®Google Scholar
• Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011;18(1):18–25. Jan
   PubMed Web of Science ®Google Scholar
• Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol. 2003;15(21(14):2664–2672. Jul
   Google Scholar
• Shitara K, Munakata M, Muto O, Okada R, Mitobe S, Mino M, Ikami I, Sakata Y. Hepatic arterial infusion of oxaliplatin for a patient with hepatic metastases from colon cancer undergoing hemodialysis. Jpn J Clin Oncol. 2007;37(7):540–543. Jul
   PubMed Web of Science ®Google Scholar
• Hann A, Nosalski E, Hermann PC, Egger J, Seufferlein T, Keller F. Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review. CN. 2018;90(2):125–141. Aug
   Google Scholar
• Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978;6(6):547–558. Dec
   PubMedGoogle Scholar
• Qiu M-Z, Li Q, Wang Z-Q, Liu T-S, Liu Q, Wei X-L, Jin Y, Wang D-S, Ren C, Bai L, et al. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. Int J Cancer. 2014; May 15134(10):2468–2477.
   PubMed Web of Science ®Google Scholar
• Katsumata K, Sumi T, Wada T, Mori Y, Hisada M, Kawakita H, Enomoto M, Suzuki S, Matsuda D, Tsuchida A, et al. Oxaliplatin for metastatic colon cancer in a patient with renal failure. Clin Med Oncol. 2008;2:97–101.
   PubMedGoogle Scholar
• Gori S, Lunardi G, Inno A, Magarotto R, Duranti S, Messa MG, Mucchino C, Cirillo M. Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis. Clin Colorectal Cancer. 2014;13(4):260–263. Dec
   PubMed Web of Science ®Google Scholar
• Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6(4):1205–1218. Apr
   PubMed Web of Science ®Google Scholar
• Allain P, Heudi O, Cailleux A, Le Bouil A, Larra F, Boisdron-Celle M, Gamelin E. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos. 2000;28(11):1379–1384. Nov
   PubMed Web of Science ®Google Scholar
• Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993;53(24):5970–5976. Dec 15
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Silvestris N, Santoro A, Secondino S, Brunetti O, Longo V, Mancini E, Mariucci S, Rampino T, Delfanti S, et al. Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Societa Italiana di Nefrologia (SIN). ESMO Open. 2017;2(3):e000167.
   PubMed Web of Science ®Google Scholar
• Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med. 1979;93(3):449–458. Mar
   PubMed Web of Science ®Google Scholar
• Perez-Flores I, Coronel F, Cigarran S, Herrero JA, Calvo N. Relationship between residual renal function, inflammation, and anemia in peritoneal dialysis. Adv Perit Dial. 2007;23:140–143.
   PubMedGoogle Scholar
• Gusella M, Rebeschini M, Cartei G, Ferrazzi E, Ferrari M, Padrini R. Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure. Ther Drug Monit. 2005;27(6):816–818. Dec
   PubMed Web of Science ®Google Scholar
• Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, et al. 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers (Basel. 2010;2(3):1717–1730. ). Sep 17
   PubMedGoogle Scholar
• Catalano V, Bisonni R, Graziano F, Giordani P, Alessandroni P, Baldelli AM, Casadei V, Rossi D, Fedeli SL, D’Emidio S, et al. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer. 2013;16(3):411–419. Jul
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351. Jun 3
   PubMed Web of Science ®Google Scholar